George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 Apr 11. doi: 10.1007/s41669-024-00483-w
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Sebastian J, Cai l, Williamson D, Foushee B, Kam-Morgan L, Eisenberg MT. Identification and characterization of two novel sequence variants in the Thrombopoietin Receptor (MPL) gene using data from 8700 JAK-2 V617F negative patients. Poster presented at the 2016 Association for Molecular Pathology (AMP) Annual Meeting; November 10, 2016. Charlotte, NC. [abstract] J Mol Diagn. 2016 Nov; 18(6):955. doi: 10.1016/S1525-1578(16)30176-3
Muth MK, Zhen C, Taylor J, Cates S, Kosa K, Zorn D, Choiniere C. The value to consumers of health labeling statements on breakfast foods and cereals. Journal of food products marketing. 2013 Jul;19(4):279-98. doi: 10.1080/10454446.2013.724372